A Small Anxiety Trial Tested 30 mg of CBD a Day

A McLean Hospital pilot tested 30 mg a day for six weeks

Many well-known CBD anxiety trials have used 300 mg, 600 mg, or even 800 mg a day. Those amounts are ten to more than twenty times the 30 mg tested in this pilot, so their results cannot be applied directly to the lower dose.

A team at McLean Hospital, a Harvard Medical School affiliate, tested 30 mg a day instead. The researchers chose a full-spectrum product and dose intended to resemble products already sold to consumers.

What the trial did

Twelve patients completed the six-week trial. Nine were women and three were men, aged 22 to 64. All had at least moderate anxiety based on their scores on the study’s screening measures.

Participants took 0.5 mL of a hemp-derived, full-spectrum, high-CBD sublingual solution twice a day, for a target of 30 mg of CBD daily. The researchers weighed the bottles at each visit and compared the results with the participants’ diaries. Average intake was 31.29 mg a day, close to the target.

Participants attended seven weekly visits. The researchers measured anxiety five ways, using self-report scales and a clinician-rated interview.

What changed over six weeks

• Every anxiety measure fell significantly. The self-reported Beck Anxiety Inventory (p < 0.001), the OASIS impairment scale (p < 0.001), state anxiety (p = 0.022), trait anxiety (p = 0.005), and the clinician-rated Hamilton scale (p < 0.001)
• The change appeared in the first week. After seven days, 91.67% of participants had reached at least a 15% reduction on the Beck inventory. By two weeks, every participant had reached that threshold and maintained it through the trial.
• Depression scores fell (p < 0.001), positive mood rose (p = 0.003), and negative mood fell (p < 0.001).
• Sleep quality improved (p < 0.035)
• Quality of life improved on several measures, including energy, emotional well-being, and social functioning.
• Thinking and memory did not get worse. Performance on tests of executive function and memory stayed stable or improved

Three adverse events were recorded across the trial, none of them serious.

Why the 30 mg dose drew attention

Most CBD anxiety trials have used much larger doses than the McLean study. A result at 300 mg or 600 mg does not tell us what to expect from a 30 mg serving.

The McLean team designed this pilot to examine a dose and cannabinoid profile closer to products already on the market. They also used the types of clinical measures that could be carried into a larger trial.

The results do not prove that 30 mg of CBD reduces anxiety. They do provide six weeks of closely monitored data at a lower dose than most earlier clinical research.

The missing placebo group

There was no placebo group, and everyone knew they were taking CBD. At the start, all 12 participants expected the product to help. Nine expected their anxiety to improve a little, and three expected it to improve significantly.

Those expectations could have contributed to the reported improvement, but this study cannot tell us how much. The authors call for double-blind, placebo-controlled studies before drawing firm conclusions about products like the one tested.

What five different measures add

Anxiety trials often report a single scale, but this pilot used five. Two were self-report questionnaires, two distinguished current anxiety from a person’s usual level of anxiety, and one was a clinician-rated interview.

All five measures improved. The clinician-rated measure does not rely on participants assigning their own scores, but the paper does not describe the clinician as blinded to treatment. It therefore does not provide an independent check on the missing placebo group.

The five measures show that the improvement appeared across several ways of assessing anxiety. They do not show that CBD caused it.

What a supporting study adds

A larger single-arm trial at higher doses (2026, European Psychiatry): Researchers at the Federal University of Paraíba in Brazil ran a prospective trial in adults with anxiety symptoms, starting at 50 mg a day and increasing by 50 mg every two weeks up to a maximum of 200 mg a day, over eight weeks.

• 65 people enrolled and 51 completed, with six stopping because they could not tolerate the extract and eight lost to follow-up
• Beck Anxiety Inventory scores fell from 35.7 to 12.2
• The proportion scoring in the severe range fell from 74.5% to 21.6%
• The intention-to-treat analysis gave a mean improvement of 24.0 points (95% CI 20.4 to 27.8, p < 0.001)
• Side effects were mostly digestive: nausea in seven people, drowsiness in six, diarrhea in four

The Brazilian trial has the same main weakness as the McLean pilot: it had no control group. It was also published as a conference abstract rather than a full paper. The study included more participants and allowed doses from 50 mg to 200 mg a day according to tolerance, but it did not report outcomes separately for each dose.

What the trial did not set out to answer

The McLean trial did not compare CBD with a placebo, an established anxiety treatment, or another dose. As a small pilot, it was designed to gather preliminary safety and outcome data that could inform a larger controlled trial.

It also did not study ordinary day-to-day stress. Participants entered with at least moderate anxiety on the Beck Anxiety Inventory or the OASIS anxiety and impairment scale, and they were monitored weekly.

The trial ran for six weeks, so it does not tell us what happens after several months or after someone stops taking the product.

What this means for you

The safety picture

Both trials reported mostly mild side effects and no serious ones. In the larger study, six of 65 participants stopped because they could not tolerate the extract, most often because of digestive effects. CBD can also interact with prescription medications, so anyone taking medication should check with a pharmacist or clinician before using it.

The endocannabinoid connection

The endocannabinoid system helps regulate stress responses and is present in everyone. These trials, however, enrolled people with at least moderate or clinically significant anxiety and monitored them in a research setting.

The everyday connection

The McLean trial is unusual because it tested 30 mg a day, a dose chosen to resemble consumer use. Whether that amount affects ordinary work stress is a separate question, and neither trial studied it.

Worth keeping in mind

• The McLean trial included 12 people. It was a small pilot designed to prepare for larger research.
• No placebo group in either trial. Participants knew they were taking a CBD-rich extract, so the studies cannot separate treatment effects from expectations or other changes over time.
• Both trials enrolled people with clinically significant anxiety symptoms. They were not studies of everyday stress.
• The Brazilian study is a conference abstract, so it has had less scrutiny than a full paper.
• The McLean study product was a specific full-spectrum hemp extract, not CBD isolate, and formulation affects how much reaches the bloodstream.
• Symptoms improved early in the McLean trial. Without a placebo group, the study cannot tell us why the change appeared within the first week.

The McLean pilot gives researchers a reason to test a 30 mg dose in a larger placebo-controlled trial. Until that happens, it remains preliminary evidence from 12 participants rather than proof that the dose works.

---

About the original studies

Title: Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study

Published: August 2025, Biomedicines

Authors:

• Rosemary T. Smith, Cognitive and Clinical Neuroimaging Core, McLean Hospital, Belmont, Massachusetts
• Mary Kathryn Dahlgren, Cognitive and Clinical Neuroimaging Core, McLean Hospital
• Kelly A. Sagar, Cognitive and Clinical Neuroimaging Core, McLean Hospital
• Deniz Kosereisoglu, Cognitive and Clinical Neuroimaging Core, McLean Hospital
• Staci A. Gruber, Cognitive and Clinical Neuroimaging Core, McLean Hospital

Link: https://doi.org/10.3390/biomedicines13081874

Title: Evaluation of the Anxiolytic Potential and Tolerability of a CBD-Rich Cannabis Extract in Adults with Anxiety: Results from a Single-Arm Clinical Trial

Published: 2026, European Psychiatry (conference abstract)

Authors:

• I. T. Moreira and colleagues, Federal University of Paraíba, João Pessoa, Brazil

Link: https://doi.org/10.1192/j.eurpsy.2026.11232

---